Q2866735 (Q2866735): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): InsideTumorCells intends to patently protect the IP rights of a new cancer medicine that releases the drug into tumour cells, minimising side effects., translated_summary) |
||||||||||||||
Property / summary | |||||||||||||||
InsideTumorCells intends to patently protect the IP rights of a new cancer medicine that releases the drug into tumour cells, minimising side effects. (English) | |||||||||||||||
Property / summary: InsideTumorCells intends to patently protect the IP rights of a new cancer medicine that releases the drug into tumour cells, minimising side effects. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / summary: InsideTumorCells intends to patently protect the IP rights of a new cancer medicine that releases the drug into tumour cells, minimising side effects. (English) / qualifier | |||||||||||||||
point in time: 7 July 2021
|
Revision as of 01:07, 7 July 2021
Project Q2866735 in Portugal
Language | Label | Description | Also known as |
---|---|---|---|
English | No label defined |
Project Q2866735 in Portugal |
Statements
42,500.0 Euro
0 references
76.0 percent
0 references
18 June 2019
0 references
15 February 2022
0 references
UNIVERSIDADE DE COIMBRA
0 references
InsideTumorCells pretende proteger por patente os direitos de PI de um novo medicamento para o cancro que liberta o fármaco dentro das células tumorais, minimizando os efeitos secundários. (Portuguese)
0 references
InsideTumorCells intends to patently protect the IP rights of a new cancer medicine that releases the drug into tumour cells, minimising side effects. (English)
7 July 2021
0 references
Coimbra
0 references
Identifiers
CENTRO-01-0145-FEDER-042773
0 references